Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a promising biotechnology company due to their innovative approach to treating mental health conditions and potential for significant market opportunity with their COMP360 drug. The company's strong financials and successful trials, along with the FDA's support for psychedelic therapies and their focus on mood disorders and psychiatric diseases, make them a promising contender in the market. While there are risks involved with navigating regulations and maintaining exclusivity, the company's potential for international partnerships and partnerships in the US market could solidify their position as a major player in the industry. Additionally, the increasing acceptance of psychedelic drugs in treatment-resistant depression and potential for use in PTSD patients shows the growing demand for alternative treatment options, making Compass Pathways an attractive investment for a financial analyst.

Bears say

Compass Pathways is taking a measured approach to commercialization and setting realistic expectations for initial sales in '27, with potential upside due to efficiencies in administration and room utilization, but concerns remain around potential challenges with REMS and infrastructure. The company's partnership with the VA for studies in PTSD indicate a potential $1.4B peak sales opportunity in this indication. However, concerns regarding ESG considerations and potential risks in clinical development, commercialization, and pricing pose potential downside risks. The current valuation may not fully account for these potential risks and investors should approach this stock with caution.

COMPASS Pathways (CMPS) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 11 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jul 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.